Organogenesis Holdings (ORGO) Gains from Sales and Divestitures (2022 - 2026)

Organogenesis Holdings' Gains from Sales and Divestitures history runs 5 years deep, the most recent figure standing at $397800.0 for Q1 2026.

• In Q1 2026, Gains from Sales and Divestitures fell 74.87% year-over-year to $397800.0; the TTM figure through Mar 2026 stood at $397800.0 (down 74.87% YoY), while the FY2025 annual figure was $1.6 million, up 14.32% from the prior year.
• Gains from Sales and Divestitures was $397800.0 for Q1 2026 at Organogenesis Holdings, down from $1.6 million in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $1.6 million in Q4 2025 to a low of $239245.0 in Q2 2022.
• Historically, Gains from Sales and Divestitures has averaged $948088.6 across 5 years, with a median of $949694.0 in 2023.
• The sharpest annual moves came in 2024 and 2026: Gains from Sales and Divestitures soared 230.35% in 2024, then plunged 74.87% in 2026.
• A 5-year view of Gains from Sales and Divestitures shows it stood at $249106.0 in 2022, then jumped by 109.81% to $522651.0 in 2023, then jumped by 174.53% to $1.4 million in 2024, then rose by 14.32% to $1.6 million in 2025, then slumped by 75.75% to $397800.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $397800.0 (Q1 2026), $1.6 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.